Cancer Gene Therapy Market Share, Growth, Demand and Future Analysis

Increasing funding for R&D activities for cancer gene therapy, rising prevalence of cancer, rapid technological advancements, growing geriatric population, ethical acceptance of gene therapy for treatment of diseases, growing popularity of DNA vaccines and favorable government regulations are some of the key factors characterizing the growth in the cancer gene therapy market, globally. According to the American Cancer Society, around 1,688,780 new cancer cases are expected to be diagnosed, in the U.S., in 2017. Almost, 600,920 Americans are expected to die of cancer in 2017, indicating that around 1,650 cancer patients are dying per day, due to the disease. In 2013, the World Health Organization (WHO) launched the Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013-2020, that aimed at reducing the rate of premature mortality from cancer, cardiovascular diseases, diabetes, and chronic respiratory diseases by 25%, by 2025.

 Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/cancer-gene-therapy-market/report-sample

 Innovation therapies with better success rates, ethical acceptance of gene therapy for cancer treatment and untapped markets in developing economies are expected to offer various growth opportunities for the players in the cancer gene therapy market. For instance, in August 2017, the United States Food and Drug Administration (USFDA) approved a breakthrough treatment for children suffering with acute lymphoblastic leukemia (ALL) using CAR T therapy, also known as Kymriah, developed at the University of Pennsylvania’s Abramson Cancer Center.
In November 2017, ZIOPHARM Oncology, Inc. announced positive data updates supporting survival benefit and the underlying immune system mechanism for Ad-RTS-hIL-12 plus veledimex, the company's controlled human interleukin-12 (hIL-12) gene therapy candidate for brain cancer, at the 22nd Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO).
In June 2017, Cell Medica acquired the Catapult Therapy TCR Limited, a subsidiary of Cell and Gene Therapy Catapult (CGT Catapult), and initiated a collaboration to establish cell therapy manufacturing for Cell Medica at CGT Catapult’s GMP manufacturing facility in Stevenage, the U.K. Some of the other key players operating in the cancer gene therapy industry include Genelux Corporation, Cell Genesys, Advantagene Inc., GenVec, Inc., BioCanCell Ltd.,  Adaptimmune Therapeutics plc, Bluebird bio, Inc., and Achieve Life Sciences, Inc.
About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
Connect with us: LinkedIn | Twitter | Google + | Facebook

Comments

Post a Comment